|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||4.5800 - 4.6800|
|52-week range||4.5800 - 4.6800|
|Beta (5Y monthly)||1.95|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Cancer diagnostics specialist Oncocyte (NYSEMKT: OCX) rose at a double-digit pace on Friday on news that it's tapping the stock market for a new round of capital-raising. Oncocyte priced its previously announced underwritten secondary stock issue of 7.78 million shares at $4.50 apiece. If all goes well, this should bring in gross proceeds of roughly $35 million.
OncoCyte Corporation (NYSEMKT:OCX) shareholders will have a reason to smile today, with the analysts making...